Barclays PLC Maravai Lifesciences Holdings, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Maravai Lifesciences Holdings, Inc. stock. As of the latest transaction made, Barclays PLC holds 184,189 shares of MRVI stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

184,189

Previous 184,189 -0.0%

Holding current value

$1.04 Million

Previous $1.53 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$6.84 - $9.73 $979,378 - $1.39 Million	143,184 Added 349.19%	184,189 $1.53 Million
Q2 2024 Aug 14, 2024	BUY	$6.87 - $11.34 $93,734 - $154,722	13,644 Added 49.87%	41,005 $294,000
Q1 2024 May 15, 2024	BUY	$5.11 - $8.76 $17,292 - $29,643	3,384 Added 14.11%	27,361 $236,000
Q4 2023 Feb 15, 2024	SELL	$4.7 - $9.87 $1,104 - $2,319	-235 Reduced 0.97%	23,977 $157,000
Q3 2023 Nov 07, 2023	BUY	$9.14 - $12.85 $4,442 - $6,245	486 Added 2.05%	24,212 $241,000
Q2 2023 Aug 03, 2023	SELL	$12.09 - $15.0 $181,470 - $225,150	-15,010 Reduced 38.75%	23,726 $295,000
Q1 2023 May 04, 2023	BUY	$12.99 - $16.48 $429,059 - $544,334	33,030 Added 578.86%	38,736 $543,000
Q4 2022 Feb 13, 2023	SELL	$12.5 - $24.78 $61,137 - $121,198	-4,891 Reduced 46.15%	5,706 $81,000
Q3 2022 Nov 03, 2022	BUY	$20.6 - $30.37 $24,452 - $36,049	1,187 Added 12.61%	10,597 $270,000
Q2 2022 Aug 12, 2022	BUY	$26.05 - $37.48 $117,719 - $169,372	4,519 Added 92.39%	9,410 $268,000
Q1 2022 May 16, 2022	BUY	$24.46 - $40.92 $119,633 - $200,139	4,891 New	4,891 $172,000

Others Institutions Holding MRVI

# of Institutions

235

Shares Held

141M

Call Options Held

223K

Put Options Held

19.4K

View Full List

About MARAVAI LIFESCIENCES HOLDINGS, INC.

Ticker MRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 131,540,000
Market Cap $739M
Description
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for dia...

More about MRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account